(c) names of the manufacturers and the composition of each product?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) to (c) A statement giving the information to the extent available is attached. [*See* Appendix CXXXVII, Annexure No. 13] It may be mentioned that most of these formulations are price decontrolled under the Drugs Prices Control Order, 1979.

Losses incurred to IDPL units

846. SHRI K. MOHANAN: Will the Minister of INDUSTRY be pleased to state:

(a) which of the units of the Indian Drugs and Pharmaceuticals Limited are losing ones, with reasons for such loss in details;

(b) what action was taken to prevent such losses unit-wise; and

(c) what are the reasons therefor, whether any person could be pinpointed for such loss; if so, the details thereof and the measures initiated to rectify the reasons for such losses or to punish the persons responsible for such loss?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (c) All units of I.D.P.L. are incurring losses. The losses are due to various factors including under utilisation of installed capacity excess manpower at certain levels, technological problems, higher cost of production from basic stage and product-mix predominently comprising category I and II bulk drugs and formulations with lower mark-up.

(b) In-house task force was constituted in December, 1985 by IDPL to identify the constraints and opportunities and to come out with concrete plans for rehabilitation and revival. In order to catalyse the functioning of this team two consultants were associated by the Company with the task force on a part time basis.

Proposal for closing down the IDPL

847. SHRI N. E. BALRAM: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the Chairman of the Indian Drugs and Pharmaceuticals Limited has recently proposed to shut down its Madras plant; to give away the Muzaffarpur plant to another company and thus to reduce the total production to ten bulk drugs.

(b) if so, what are the details thereof and the reasons therefor; and

(c) what is Government's reaction thereto?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) According to IDPL there is no such proposal at present.

(b) and (c) Do not arise.

Prices to drugs

848. SHRI N. E. BALRAM: Will the Minister of INDUSTRY be pleased to state:

(a) whether Government are aware that there has been continued increase in prices of drugs; and

(b) if so, what steps are being taken by Government to control the prices of all the medicines?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (b) The prices of medicines have been moderated because of the Drugs (Prices Control) Order, 1979. However, the position has been taken note of while formulating the New Drug Policy.

Ratio parameters of bulk drugs

849. PROF. B. RAMACHANDRA RAO:
PROF. (MRS.) ASIMA CHATTERJEE:

Will the Minister of INDUSTRY be pleased to state:

(a) what are the ratio parameters of Bulk drug to Formulation Production-fixed by the Government for the Indian and FERA and Ex-FERA Companies;

(b) what was the actual position during 1976-77 and 1982-83;

(c) if the actual figures are different from those stipulated what are the reasons thereof; and

(d) the action proposed to be taken by Government to rectify this imbalance?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) According to 1978 Drug Policy a FERA company will be granted fresh industrial licence for formulations, *inter-alia*, only ig the ratio of bulk drug consumption to that of formulations is 1:5. Similarly, other companies will be allowed formulation licences upto 10 times of the value of their bulk drug production.

(b) The concept of ratio parameters were not in existence during 1976-77. All companies in the organised sector fulfilled the conditions of ratio parameters during 1982-83 except 14 companies listed below:

1. M/s. Abbott Labs. (I) Pvt. Ltd.
2. M/s. Chowgule & Co. (Hind) Pvt. Ltd.,
3. M/s. Deys' Medical Stores (Mfg.) Ltd.,
4. M/s. Amrutanjan Limited
4. M/s. J. L. Morison & Jones (I) Ltd.,
6. M/s. Orient Pharma (P) Ltd..
7. M/s. Dabur Limited
8. M/s. Smith, Kline & French
9. M/s. Roussel Pharmaceutical Limited
10. M/s. Warner Hindustan Limited
11. M/s. Anglo French
12. M/s. E. Merck (I) Limited
13. M/s. Sandoz (I) Limited
14. M/s. Tamilnadu Dhadha Pharmaceuticals Limited

(c) and (d) None of the above companies have been granted fresh licences for additional formulations in relaxation of the drug policy parameters. It may also be mentioned that since 1982-83 M/s. Sandoz (I) Limited, M/s. E. Merck and M/s. Tamilnadu Dhada Pharmaceuticals have increased their bulk drug production and they now conform to the ratio parameter. M/s. Abbott Labs. and M/s. Roussel Pharmaceuticals Limited have since reported production of bulk drugs.

Updating technologies of certain drugs by IDPL

850. SHRI MAHENDRA MOHAN MISHRA: Will the Minister of INDUSTRY be pleased to state:

(a) whether his attention has been drawn to the news which appeared in 'Financial Express' dated the 29th January, 1986 under the heading 'IDPL may turn corner by next year';

(b) if so, whether it is a fact that IDPL has decided to update the technologies of certain drugs where production is not economical;

(c) whether it is a fact that those drugs are being produced by other drug companies in the country with indigenously developed technologies and found the process very successful;

(d) if so, names of those companies alongwith the name of each drug and production during the last three years, year-wise;